Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Gemcitabine Plus UFTE Combination Chemotherapy as Salvage Treatment in Oxaliplatin, Irinotecan and Fluoropyrimidine-Refractory Metastatic Colorectal Cancer

NCT01409005 is registered in ClinicalTrials.gov with Seoul National University Bundang Hospital as lead sponsor.

NCT NCT01409005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01409005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Gemcitabine Plus UFTE Combination Chemotherapy as Salvage Treatment in Oxaliplatin, Irinotecan and Fluoropyrimidine-Refractory Metastatic Colorectal Cancer
Lead sponsor
Seoul National University Bundang Hospital
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
Not reported
Enrollment
41 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic or recurrent colorectal cancer, refractory to fluoropyrimidine, oxaliplatin and irinotecan, salvage chemotherapy